David H. Schaer

David H. Schaer, M.D., F.A.C.C. Dr.Schaer is board certified in Interventional Cardiology and Cardiovascular Diseases. Dr Schaer has been listed in 'America's Best Doctors.' In addition to his position at Cardiology Associates, he has served as the Editor of New Jersey Cardiology, the newsletter for the N.J. Chapter of the American College of Cardiology. Dr. Schaer has also served as an officer at Anshe Emeth Memorial Temple in New Brunswick. He helped to found the Partners in Education program where local professionals work with teachers in inner-city schools. Dr. Schaer writes music for piano and performs annually at Robert Wood Johnson University Hospital during the Physicians and Their Arts Festival. Dr. Schaer lives in East Brunswick with his family.

Peter Stone

Peter Stone, MD, Dr.Stone is Associate Professor of Medicine, Harvard medical School; Co-Director of Cardiac Care Unit, Co-Director of Samuel Levine Cardiac Unit, Department of Cardiology, Brigham and Woman’s Hospital. Dr.Stone graduated from Weill Medical College of Cornell University, finished his Medical Residency from University of California San Francisco, and Cardiology Fellowship from Pacific Medical Center of San Francisco. Dr. Stone 's research interests focus on a variety of aspects concerning coronary artery disease, from understanding the basic and clinical vascular biology of atherosclerosis progression in animals and in man, to investigating new pharmacologic and device therapies for patients with acute and chronic coronary artery disease.

David Lee

Dr. Lee is an associate professor at Harvard Medical School and the Director of the Bioorganic and Natural Products Laboratory at McLean Hospital. He completed his Ph.D. degree in Natural Products Chemistry at Columbia University. Dr. Lee has worked on numerous projects in drug discovery and development related to traditional Chinese medicine. He and his team isolated a potent topoisomerase I inhibitor (NPI-BC-4) from Boswelliacaterii, a traditional medicine used in the treatment of inflammatory diseases in India and China without overt toxicity. A preliminary clinical trial of NPI-BC-4 in Germany showed excellent results in patients with brain tumors. Because of its specific activity against CNS (SP-295) and prostate cancer cell lines (DU-145 and PC-3), NPI-BC-4 is also being developed as a potential non-hormonal therapy for advanced prostate cancer and for early intervention, including benign prostate hyperplasia. Dr. Lee has contributed significantly to the development of alternative therapies for substances abuse. He is the principal investigator on a program project grant funded by the National Institutes of Health entitled “Alternative Therapies for Alcohol and Drug Abuse.” Under this program, several isoflavone glycosides have been identified and assessed in animal models of alcoholism. Because of their favorable toxicity profile in comparison with naltrexone, an FDA approved drug, and their suppression of alcohol drinking in alcohol preferring rats, these isoflavone glycosides stand a good chance of development for the treatment of alcoholism. Dr. Lee is also serving as Co-PI on the development of the herbal remedy (HLXL) for osteoarthritis. Dr. Lee and his colleagues at McLean Hospital are also looking into natural remedies for depression, insomnia, and Alzheimer’s disease. Dr. Lee received an institutional development award in 1985. He has published 100 papers and holds 15 U.S. and international patents. He is executive committee member of ACMES and associate editor of North American Journal of Medicine and Health.

Myron Tong

Myron Tong, MD, PhD; Professor of Medicine and Surgery, Phleger Liver Institute, Division of Digestive Diseases, Director of Hepatology, Associate Director, UCLA Liver Cancer Center, David Geffen School of Medicine at the University of California in Los Angeles

Rohit Arora

Rohit Arora, MD, FACC, FAHA, FACP, FSCAI, Professor of Medicine, Professor of Physiology and Biophysics, Chairman of Cardiology, Associate Chairman of Medicine for Research, The Chicago Medical School, Chicago, IL

Wendy Qiu

Wendy Qiu, MD, PhD: Dr.Qiu is an Associate Professor of Boston University School of Medicine, Departments of Psychiatry and Pharmacology & Experimental Therapeutics. Dr. Qiu’s research goal is to develop diagnostic tools and effective treatments for Alzheimer’s disease (AD) and other diseases in geriatric psychiatry. Dr. Qiu sees patients in the Alzheimer’s disease Center and also serves as a co-investigator for the clinical trials and clinical studies including ADAPT, HOPE and ADNI. Dr.Qiu published many peer review articles in the field of geriatric psychiatry. Dr. Qiu has received multiple awards for her research, including the Vincent du Vigneaud Prize, the Psychiatry Resident Award by Pfizer, and the CREFF Award.

Jason Chen

Jason Chen, PhD: Dr. Jason Chen received his B.Sc. from Shandong University, China in 1982 and Ph.D. in microbiology from Columbia University in 1991. As a graduate student at Columbia University, he engaged in the genetic and biochemical studies of the herpes simplex virus. Dr. Chen did his postdoctoral work at New England Medical Center/Tufts University School of Medicine, Boston, USA. As a postdoc, he identified the first p53-independent protein-binding partner of HPV E6. Dr. Chen is currently an Associate Professor at the University of Massachusetts Medical School, USA. He is a Guest Professor of Shandong University. Dr. Chen's main research interests include cancer biology, virology, anti-viral and anti-cancer therapy. Dr. Chen is an Associate Editor for North American Journal of Medicine and Science and editorial board member for several other journals.

Raymond Mak

Raymond Mak, M.D. Dr.Mak is the Instructor, Department of Radiation Oncology, Brigham and Women’s Hospital/Dana-Farber Cancer Institute and Harvard Medical School, specialize in radiation therapy for lung cancer and other thoracic malignancies, and in stereotactic body radiation therapy for the management of early stage lung cancer. His research interests include developing clinically-applicable genetic predictors of response to radiation therapy in non-small cell lung cancer, with a focus on characterizing radiosensitivity based on tumor genotype and germline genetic analysis for prediction of increased risk of radiation-induced normal tissue toxicity.